Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age

OBJECTIVES: Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old; comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy. Nivolumab is the only immunotherapy to significantly improve overall survival (OS) versus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oral Oncol
Main Authors: Saba, Nabil F., Blumenschein, George, Guigay, Joel, Licitra, Lisa, Fayette, Jerome, Harrington, Kevin J., Kiyota, Naomi, Gillison, Maura L., Ferris, Robert L., Jayaprakash, Vijayvel, Li, Li, Brossart, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7723820/
https://ncbi.nlm.nih.gov/pubmed/31422216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2019.06.017
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados